RxDoctor Payments Data

Scott Vincent, MD

Orthopaedic Surgery · Omaha, NENPI 1912291469

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,063 of the $5,029 with a category attached, or 60.9%. 4 manufacturers reported payments, led by Globus Medical at 46.4% of the total. Reporting peaked in 2019 at $2,307 and has fallen 62.5% since, to $866 in 2025.

$5,029in general payments, 2019–2025

Across 53 payments — averaging $94.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$2K
  • Medtronic$2K
  • Cerapedics Inc.$889
  • Kuros Biosciences USA, Inc$292

What the payments were for

  • Travel & lodging$1,93739%
  • Food & beverage$3,06361%
  • Entertainment$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Globus Medical12$2,334
Medtronic(2 entities)21$1,514
Cerapedics Inc.18$889
Kuros Biosciences USA, Inc2$292

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,029 in reported general payments places this provider in the 60th percentile of 155 orthopaedic surgery providers in Nebraska.

See all orthopaedic surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$139,315
Medicare patients
249
Services billed
602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib33$2,011
Gabapentin37$468
Meloxicam51$135
Methylprednisolone14$111

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →